Cannabidiol and SARS-CoV-2 Infection
Cannabidiol (CBD) can prevent the inflammatory response of SARS-CoV-2 spike protein in Caco-2-cells. This action is coupled with the inhibition of IL-1beta, IL-6, IL-18, and TNF-alpha, responsible for the inflammatory process during SARS-CoV-2 infection. CBD can act on the different proteins encoded...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.870787/full |
| _version_ | 1819174493634953216 |
|---|---|
| author | Alexandre Vallée |
| author_facet | Alexandre Vallée |
| author_sort | Alexandre Vallée |
| collection | DOAJ |
| description | Cannabidiol (CBD) can prevent the inflammatory response of SARS-CoV-2 spike protein in Caco-2-cells. This action is coupled with the inhibition of IL-1beta, IL-6, IL-18, and TNF-alpha, responsible for the inflammatory process during SARS-CoV-2 infection. CBD can act on the different proteins encoded by SARS-CoV-2 and as an antiviral agent to prevent the viral infection. Furthermore, recent studies have shown the possible action of CBD as an antagonist of cytokine release syndromes. In the SARS-CoV-2 pathophysiology, the angiotensin-converting enzyme 2 (ACE2) seems to be the key cell receptor for SARS-CoV-2 infection. The WNT/β-catenin pathway and PPARγ interact in an opposite manner in many diseases, including SARS-CoV-2 infection. CBD exerts its activity through the interaction with PPARγ in SARS-CoV-2 infection. Thus, we can hypothesize that CBD may counteract the inflammatory process of SARS-CoV-2 by its interactions with both ACE2 and the interplay between the WNT/β-catenin pathway and PPARγ. Vaccines are the only way to prevent COVID-19, but it appears important to find therapeutic complements to treat patients already affected by SARS-CoV-2 infection. The possible role of CBD should be investigated by clinical trials to show its effectiveness. |
| first_indexed | 2024-12-22T20:39:51Z |
| format | Article |
| id | doaj.art-6dcdd0120a68447fac3cd20055007dc0 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T20:39:51Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6dcdd0120a68447fac3cd20055007dc02022-12-21T18:13:22ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-03-011310.3389/fimmu.2022.870787870787Cannabidiol and SARS-CoV-2 InfectionAlexandre ValléeCannabidiol (CBD) can prevent the inflammatory response of SARS-CoV-2 spike protein in Caco-2-cells. This action is coupled with the inhibition of IL-1beta, IL-6, IL-18, and TNF-alpha, responsible for the inflammatory process during SARS-CoV-2 infection. CBD can act on the different proteins encoded by SARS-CoV-2 and as an antiviral agent to prevent the viral infection. Furthermore, recent studies have shown the possible action of CBD as an antagonist of cytokine release syndromes. In the SARS-CoV-2 pathophysiology, the angiotensin-converting enzyme 2 (ACE2) seems to be the key cell receptor for SARS-CoV-2 infection. The WNT/β-catenin pathway and PPARγ interact in an opposite manner in many diseases, including SARS-CoV-2 infection. CBD exerts its activity through the interaction with PPARγ in SARS-CoV-2 infection. Thus, we can hypothesize that CBD may counteract the inflammatory process of SARS-CoV-2 by its interactions with both ACE2 and the interplay between the WNT/β-catenin pathway and PPARγ. Vaccines are the only way to prevent COVID-19, but it appears important to find therapeutic complements to treat patients already affected by SARS-CoV-2 infection. The possible role of CBD should be investigated by clinical trials to show its effectiveness.https://www.frontiersin.org/articles/10.3389/fimmu.2022.870787/fullCOVID-19Wnt/β-catenin pathwayPPARγACE2cannabidiolSARS-CoV-2 |
| spellingShingle | Alexandre Vallée Cannabidiol and SARS-CoV-2 Infection Frontiers in Immunology COVID-19 Wnt/β-catenin pathway PPARγ ACE2 cannabidiol SARS-CoV-2 |
| title | Cannabidiol and SARS-CoV-2 Infection |
| title_full | Cannabidiol and SARS-CoV-2 Infection |
| title_fullStr | Cannabidiol and SARS-CoV-2 Infection |
| title_full_unstemmed | Cannabidiol and SARS-CoV-2 Infection |
| title_short | Cannabidiol and SARS-CoV-2 Infection |
| title_sort | cannabidiol and sars cov 2 infection |
| topic | COVID-19 Wnt/β-catenin pathway PPARγ ACE2 cannabidiol SARS-CoV-2 |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.870787/full |
| work_keys_str_mv | AT alexandrevallee cannabidiolandsarscov2infection |